prikaz prve stranice dokumenta Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis
  Preuzmi
PDF 1.23 MB
Znanstveni rad - Izvorni znanstveni rad
Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis
Thoracic Cancer, 14 (2023), 22; 2177-2186. https://doi.org/10.1111/1759-7714.15004
Mosleh, Berta; Schelch, Karin; Mohr, Thomas; Klikovits, Thomas; Wagner, Christina; Ratzinger, Lukas; Dong, Yawen; Sinn, Katharina; Ries, Alexander; Berger, Walter; Grasl‐Kraupp, Bettina; Hoetzenecker, Konrad; Laszlo, Viktoria; Dome, Balazs; Hegedus, Balazs; Jakopović, Marko; Hoda, Mir Alireza; Grusch, Michael Više autora...

Citirajte ovaj rad

Mosleh, B., Schelch, K., Mohr, T., Klikovits, T., Wagner, C., Ratzinger, L. ... Grusch, M. (2023). Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis. Thoracic Cancer, 14. (22), 2177-2186. doi: 10.1111/1759-7714.15004

Mosleh, Berta, et al. "Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis." Thoracic Cancer, vol. 14, br. 22, 2023, str. 2177-2186. https://doi.org/10.1111/1759-7714.15004

Mosleh, Berta, Karin Schelch, Thomas Mohr, Thomas Klikovits, Christina Wagner, Lukas Ratzinger, Yawen Dong, et al. "Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis." Thoracic Cancer 14, br. 22 (2023): 2177-2186. https://doi.org/10.1111/1759-7714.15004

Mosleh, B., et al. (2023) 'Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis', Thoracic Cancer, 14(22), str. 2177-2186. doi: 10.1111/1759-7714.15004

Mosleh B, Schelch K, Mohr T, Klikovits T, Wagner C, Ratzinger L, i sur.. Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis. Thoracic Cancer [Internet]. 21.06.2023. [pristupljeno 07.11.2024.];14(22):2177-2186. doi: 10.1111/1759-7714.15004

B. Mosleh, et al., "Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis", Thoracic Cancer, vol. 14, br. 22, str. 2177-2186, Lipanj 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:778143. [Citirano: 07.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:778143
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis
AutorBerta Mosleh
AutorKarin Schelch
AutorThomas Mohr
AutorThomas Klikovits
AutorChristina Wagner
AutorLukas Ratzinger
AutorYawen Dong
AutorKatharina Sinn
AutorAlexander Ries
AutorWalter Berger
AutorBettina Grasl‐Kraupp
AutorKonrad Hoetzenecker
AutorViktoria Laszlo
AutorBalazs Dome
AutorBalazs Hegedus
AutorMarko Jakopović
AutorMir Alireza Hoda
AutorMichael Grusch
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Background: Pleural mesothelioma (PM) is a relatively rare malignancy with limited treatment options and dismal prognosis. We have previously found elevated FGF18 expression in PM tissue specimens compared with normal mesothelium. The objective of the current study was to further explore the role of FGF18 in PM and evaluate its suitability as a circulating biomarker. Methods: FGF18 mRNA expression was analyzed by real-time PCR in cell lines and in silico in datasets from the Cancer Genome Atlas (TCGA). Cell lines overexpressing FGF18 were generated by retroviral transduction and cell behavior was investigated by clonogenic growth and transwell assays. Plasma was collected from 40 PM patients, six patients with pleural fibrosis, and 40 healthy controls. Circulating FGF18 was measured by ELISA and correlated to clinicopathological parameters. Results: FGF18 showed high mRNA expression in PM and PM-derived cell lines. PM patients with high FGF18 mRNA expression showed a trend toward longer overall survival (OS) in the TCGA dataset. In PM cells with low endogenous FGF18 expression, forced overexpression of FGF18 resulted in reduced growth but increased migration. Surprisingly, despite the high FGF18 mRNA levels observed in PM, circulating FGF18 protein was significantly lower in PM patients and patients with pleural fibrosis than in healthy controls. No significant association of circulating FGF18 with OS or other disease parameters of PM patients was observed. Conclusions: FGF18 is not a prognostic biomarker in PM. Its role in PM tumor biology and the clinical significance of decreased plasma FGF18 in PM patients warrant further investigation.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaThoracic Cancer
Brojčani podacivol. 14, br. 22, str. 2177-2186
p-ISSN1759-7706
e-ISSN1759-7714
DOIhttps://doi.org/10.1111/1759-7714.15004
URN:NBNurn:nbn:hr:105:778143
Datum objave publikacije2023-06-21
URL dokumentahttps://onlinelibrary.wiley.com/doi/10.1111/1759-7714.15004
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2023-09-25 08:59:01